99Mtc- Anionic Dendrimer Targeted Vascular Endothelial Growth Factor As a Novel Nano-Radiotracer for In-Vivo Breast Cancer Imaging Publisher Pubmed



Ebrahimi A¹ ; Pirali Hamedani M¹ ; Mohammadzadeh P¹ ; Safari M² ; Esmaeil Sadat Ebrahimi S¹ ; Seyed Hamzeh M¹ ; Shafiee Ardestani M¹ ; Masoumeh Ghoreishi S³ Show Affiliations
Source: Bioorganic Chemistry Published:2022

Abstract

Since breast cancer is the commonly cause of death among women around the world, diagnosis at the early stages is significantly important to prevent the metastasis of the cancer. Among the various growth factors that are involved in angiogenesis, vascular endothelial growth factor (VEGF) is believed to be the most important factor. Overexpressed VEGF receptor on tumors surface, is particularly interesting for cancer cells targeting purposes. In this study, citric acid dendrimer conjugated with VEGF antagonist peptide was synthesized. The obtained product was confirmed by FT-IR, TEM, DLS, and EDS. In vitro cytotoxicity assay showed no toxicity on normal cells and indicated the notably dose-dependence toxicity on cancer cells. Box-Behnken software as a computational method was used to determine the optimum amount of radiolabeling parameters. Optimized parameters for reducing agent, dendrimer-anti-VEGF, and time were 1.4 mg, 17.5 mg, and about 30 min respectively. Radiochemical purity of radio-labeled conjugated dendrimer was determined about 90 percent. SPECT imaging was done to observe the in vivo accumulation of dendrimer-anti-VEGF in the tumor site. Images showed high accumulation of radio-tracer in the tumor region. All in all, obtained results confirmed our hypothesis that the dendrimer-anti-VEGF can be a good radio-tracer for diagnosis of cancer. © 2022 Elsevier Inc.